Highlights

  • Pathkey.AI appointed AI and defence technology leader Andrew Farnsworth as CEO.
  • Farnsworth brings more than 20 years of experience across AI, Cybersecurity, defence systems, and enterprise technology.
  • The appointment supports Pathkey’s strategy to commercialise AI platforms including TrialKey and Chipforge.

Overview

Pathkey.AI Ltd (ASX:PKY) has appointed experienced AI and defence technology executive Andrew Farnsworth as its new Chief Executive Officer, effective immediately. Farnsworth brings more than two decades of experience spanning defence communications, enterprise AI, cybersecurity, infrastructure systems, and technology commercialisation. His appointment comes as Pathkey expands its focus beyond healthcare into broader AI applications for highly regulated and data-sensitive industries. Farnsworth previously advised the company during its strategic review and played a key role in shaping product strategy, Business development, and the planned Acquisition of Chipforge, an AI-powered semiconductor design platform. Management believes his experience across secure systems, AI platforms, and large-scale enterprise transformation positions the company to accelerate commercialisation opportunities for both TrialKey and Chipforge across healthcare, defence, and critical infrastructure sectors.

How Does Andrew Farnsworth’s Background Support Pathkey’s AI Strategy?

Andrew Farnsworth brings extensive experience in secure communications, AI systems, and enterprise technology transformation. His career began in the Royal Australian Air Force, where he worked on high-security communications and mission-critical IT systems. He later held senior Leadership positions across major global organisations including Yum! Brands, where he oversaw AI, Machine Learning, ecommerce, and digital platform strategies. Farnsworth also managed cybersecurity, infrastructure, and enterprise technology projects at companies including Sephora Asia and Marina Bay Sands. Pathkey believes this combination of defence-grade security expertise and commercial AI leadership aligns closely with its focus on AI applications for regulated industries.

Why Is the Chipforge Acquisition Important for Pathkey?

The planned acquisition of Chipforge represents a major strategic expansion for Pathkey into AI-powered semiconductor engineering technology. Chipforge is developing a platform designed to reduce the complexity, cost, and time associated with custom chip design using artificial intelligence. Management believes the technology could create opportunities across industries including healthcare, defence, critical infrastructure, and other highly regulated sectors. Farnsworth strongly supported the acquisition strategy and sees potential synergies between Chipforge and TrialKey, Pathkey’s Clinical Trials platform. The company aims to strengthen its AI intellectual property portfolio while accelerating near-term commercialisation opportunities across multiple industries.